High prevalence of cancer is expected to aid in growth of the monoclonal antibody therapeutics market. According to the American Cancer Society, in 2019, there will be an estimated 1,762,450 new cancer cases diagnosed and 606,880 cancer deaths in the U.S. Monoclonal immunotherapy is a successful form of immunotherapy, which makes use of monoclonal antibodies to bind to a specific antigen in cells which are specific to that disease. The primary goal is for this immunotherapy to stimulate the immune system to specifically attack these cells. Monoclonal antibodies are made by stimulating the body's own immune system through natural methods.
R&D in monoclonal antibodies is also expected to aid in growth of the monoclonal antibody therapeutics market. One of the most recent clinical trials used monoclonal antibodies to boost the immune response in patients with advanced cancer. Patients who responded to treatment had a significant improvement in their cancer survival and overall health when compared to the placebo group. This study showed promising results and was a solid step forward in the medical field. Monoclonal antibodies used in clinical trials can come in the form of single reactants or chimeric antigens. A single reactant is a single dose of an agent injected into the patient. For chimeric antigens, a molecule of a protein called a chimeramine is introduced into the body. Once the chimeric protein is introduced into the body, it will cause the production of antibodies that recognize the protein of the chimeramine. This is how monoclonal antibodies are able to recognize cancer cells and stimulate the immune system's response.
High prevalence of melanoma, lymphomas, and cervical cancers is expected to aid in growth of the monoclonal antibody therapeutics market. Other types of cancers, including melanoma, lymphomas, cervical cancers, ovarian sarcomas and head and neck cancers have also shown encouraging responses with monoclonal antibody therapy. This type of treatment could become very useful for patients in the future who are fighting these aggressive diseases.
Monoclonal antibodies are now being tested on human clinical trial participants as a possible treatment for Crohn's disease. In this study, monoclonal antibodies are administered through nasal spray, into the sinuses and into the throat to stimulate the immune system's response. These drugs are being tested on experimental Crohn's disease patients who have shown promising results in earlier clinical trials. Results from this study are expected within one year. If successful, this is expected to offer lucrative growth opportunities for players in the monoclonal antibody therapeutics market.
No comments:
Post a Comment